Delivery Order SPE2DB22D1103-SPE2DB25FTSW6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a $21,060.94 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-competitive, firm fixed price delivery order is expected to be completed by July 28, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe...
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $3,418.92. This non-competitive, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other...
- On August 15, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $97,415.40 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $74,194.57 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and specifies performance at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and...
- The Defense Logistics Agency awarded a delivery order valued at $10,545.01 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant used to treat conditions including...
- The Defense Logistics Agency awarded a delivery order valued at $7,646.70 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on July 24, 2025, with completion scheduled for July 25, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat eczema, asthma, and other...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,291.75 for Dupixent 300 mg/2 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Dupixent 300 mg/2 ml pens with a ceiling value of $43,275.69. This firm fixed-price, non-set-aside contract is scheduled for completion by August 13, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, eczema, asthma, and...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTSW6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,827.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other inflammatory conditions, supporting the Defense Health Agency's pharmaceutical supply requirements for military healthcare systems. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with the DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The prime indefinite delivery vehicle serves as a comprehensive global pharmaceutical support mechanism, enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp's significant role as a pharmaceutical prime vendor demonstrates its capability to fulfill federal medical procurement requirements through open competition, serving critical defense healthcare needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.8k | 7/28/25 |